Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Norgine sells rights for three drugs to Meda

Norgine sells rights for three drugs to Meda

16th November 2010

Norgine has announced the sale of global rights for three of its pharmaceutical agents to the Swedish firm Meda.

The company has transferred its worldwide commercial interests in Spasmonal, Pyralvex and Waxsol, subject to certain existing third party contracts, as it looks to refine the focus of its business operations.

Waxsol is sold as a treatment for the dissolution and removal of earwax, while Pyralvex allows patients to experience relief from pain caused by denture irritation and mouth ulcers.

Meanwhile, Spasmonal is specified as a therapy for smooth muscle spasms resulting from primary dysmenorrhoea, irritable bowel syndrome and painful diverticular disease of the colon.

Norgine's chief executive officer Peter Stein said: "Norgine's focus is on developing its leading position in the European specialty pharmaceutical market and we are happy that Meda can now take these products forward."

Earlier this month, Norgine announced that it has purchased a stake in fellow pharmaceutical company ProStrakan, representing 12.6 percent of its issued share capital.ADNFCR-8000103-ID-800237762-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.